{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:04:13Z","timestamp":1782252253364,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":2983,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1124\/jpet.116.233809","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T01:39:38Z","timestamp":1473298778000},"page":"280-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Renal Effects of Antisense-Mediated Inhibition of SGLT2"],"prefix":"10.1016","volume":"359","author":[{"given":"Leonie","family":"van Meer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Moerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Goulouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"de Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.233809_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2796.1999.00515.x","article-title":"A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?","volume":"246","author":"Andreev","year":"1999","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.116.233809_bib2","unstructured":"Berne R, Levy M, Koeppen B, Stanton B. Physiology. 4th, 699. 1998."},{"key":"10.1124\/jpet.116.233809_bib3","unstructured":"Bhanot S (2009) ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated [abstract 328-OR]. Diabetes Pro (American Diabetes Association) http:\/\/professional.diabetes.org\/abstract\/isis-388626-sglt2-antisense-drug-causes-robust-and-sustained-glucosuria-multiple-species (acccessed 27 August 2016)."},{"key":"10.1124\/jpet.116.233809_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI74297","article-title":"Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition","volume":"124","author":"Cefalu","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.233809_bib7","first-page":"529","article-title":"Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat","volume":"24","author":"Feinfeld","year":"1986","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1124\/jpet.116.233809_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.233809_bib9","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/ndt\/gfh426","article-title":"A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria","volume":"19","author":"Francis","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.116.233809_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0192623313505781","article-title":"Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide","volume":"42","author":"Frazier","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.116.233809_bib11","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.233809_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","article-title":"Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys","volume":"120","author":"Henry","year":"1997","journal-title":"Toxicology"},{"key":"10.1124\/jpet.116.233809_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tox.2012.06.005","article-title":"Renal uptake and tolerability of a 2\u2032-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey","volume":"301","author":"Henry","year":"2012","journal-title":"Toxicology"},{"key":"10.1124\/jpet.116.233809_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.ajkd.2010.09.024","article-title":"Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma","volume":"57","author":"Herrington","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.116.233809_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tox.2010.08.013","article-title":"Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity","volume":"277","author":"Hoffmann","year":"2010","journal-title":"Toxicology"},{"key":"10.1124\/jpet.116.233809_bib16","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1681\/ASN.V1181498","article-title":"Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans","volume":"11","author":"Honing","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.116.233809_bib17","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1517\/14656566.2014.966078","article-title":"Empagliflozin for the treatment of type 2 diabetes","volume":"15","author":"Jahagirdar","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/jpet.116.233809_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.116.233809_bib19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/jpet.116.233809_bib20","series-title":"Antisense Drug Technology: Principles, Strategies, and Application","first-page":"365","article-title":"An overview of clinical safety experience of first- and second-generation antisense oligonucleotides","author":"Kwoh","year":"2007"},{"key":"10.1124\/jpet.116.233809_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.116.233809_bib22","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0000000000000926","article-title":"CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS","volume":"83","author":"Limmroth","year":"2014","journal-title":"Neurology"},{"key":"10.1124\/jpet.116.233809_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/clinchem\/16.9.753","article-title":"Automated simultaneous determination of p-acetylaminohippurate and inulin in serum","volume":"16","author":"Looy\u00e9","year":"1970","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.116.233809_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.233809_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/019262339902700306","article-title":"Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys","volume":"27","author":"Monteith","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.116.233809_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jcla.21549","article-title":"Urinary N-acetyl-\u03b2-D-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes","volume":"26","author":"Ouchi","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"10.1124\/jpet.116.233809_bib27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2165\/11209910-000000000-00000","article-title":"Dapagliflozin: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Plosker","year":"2012","journal-title":"Drugs"},{"key":"10.1124\/jpet.116.233809_bib28","first-page":"27","article-title":"Indomethacin increases renal lithium reabsorption in man","volume":"4","author":"Rabelink","year":"1989","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.116.233809_bib29","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.116.233809_bib30","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.116.233809_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2013","journal-title":"Eur Heart J"},{"issue":"6, Suppl 1","key":"10.1124\/jpet.116.233809_bib32","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","article-title":"Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1124\/jpet.116.233809_bib33","doi-asserted-by":"crossref","first-page":"e110069","DOI":"10.1371\/journal.pone.0105638","article-title":"Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes","volume":"9","author":"Sha","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.233809_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jat.1727","article-title":"Nephrotoxicity of hexachloro-1:3-butadiene in the male Hanover Wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury","volume":"32","author":"Swain","year":"2012","journal-title":"J Appl Toxicol"},{"key":"10.1124\/jpet.116.233809_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00041552-199511000-00009","article-title":"Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance","volume":"4","author":"Toto","year":"1995","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/jpet.116.233809_bib36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.116.233809_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcph.396","article-title":"First proof of pharmacology in humans of a novel glucagon receptor antisense drug","volume":"55","author":"van Dongen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.116.233809_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","article-title":"Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9","volume":"62","author":"van Poelgeest","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.116.233809_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bcp.12282","article-title":"Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development","volume":"77","author":"van Meer","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.116.233809_bib40","unstructured":"Wancewicz EV (2008) Long term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species [abstract 334-OR]. Diabetes Pro (American Diabetes Association) http:\/\/professional.diabetes.org\/abstract\/long-term-safety-and-efficacy-isis-388626-optimized-sglt2-antisense-inhibitor-multiple (accessed 27 August 2016)."},{"key":"10.1124\/jpet.116.233809_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ki.1974.61","article-title":"Simplified measurement of p-aminohippurate and other arylamines in plasma and urine","volume":"5","author":"Waugh","year":"1974","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.116.233809_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.112.197426","article-title":"Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2)","volume":"343","author":"Zanardi","year":"2012","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419444X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419444X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.233809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:18:33Z","timestamp":1740763113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652419444X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S002235652419444X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.233809","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Effects of Antisense-Mediated Inhibition of SGLT2","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.233809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The Author(s)","name":"copyright","label":"Copyright"}]}}